OTTAWA, ON, Feb. 22, 2022 /PRNewswire/ - Tetra
Bio-Pharma Inc ("Tetra" or the
"Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a
leader in cannabinoid-based drug discovery and development, today
announced it has signed a Licensing Agreement with Thorne
Health Tech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN),
a leader in developing innovative solutions for a personalized
approach to health and wellbeing, for the commercialization of its
patent protected prebiotic dietary supplement in the
U.S. market. The Agreement will include royalty on sales and
milestone payments. The prebiotics market size in the United States is expected to exceed
USD 9.5bn by 2027 with a strong CAGR
of 9.6% in 2021⃰.
"Thorne has an established
reputation as a world leader in the sales and distribution of
evidence-based supplements for consumer self-care and
physician-directed therapies and Tetra is excited to partner with
them to bring this product to market," said Guy Chamberland, CEO of Tetra Bio-Pharma.
⃰= Global Marketing Insights (GMI) Insights to Innovation
April 14, 2021
About Thorne HealthTech
Thorne HealthTech is a
leader in developing innovative solutions for a personalized
approach to health and wellbeing. Thorne HealthTech is a
science-driven wellness company that is utilizing testing and data
to create improved product efficacy and deliver personalized
solutions to consumers, health professionals, and corporations.
Thorne HealthTech's unique, vertically integrated brands,
Thorne and Onegevity, provide
insights and personalized data, products, and services that help
individuals take a proactive and actionable approach to improve and
maintain their health over a lifetime.
About Tetra Bio-Pharma
Tetra Bio-Pharma is a
leader in cannabinoid-derived drug discovery and development with a
FDA and a Health Canada cleared clinical program aimed at bringing
novel prescription drugs and treatments to patients and their
healthcare providers. Tetra's evidence-based scientific approach
has enabled them to develop a pipeline of cannabinoid-based drug
products for a range of medical conditions, including pain,
inflammation, and oncology. With patients at the core of what they
do, Tetra Bio-Pharma is focused on providing rigorous scientific
validation and safety data required for inclusion into the existing
biopharma industry by regulators, physicians, and insurance
companies.
For more information visit: www.tetrabiopharma.com
Neither the TSX Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events, or
developments that the Company believes, expects or anticipates will
or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the success of this
product or any other product, the applicability of the
discoveries made therein, the successful and timely completion and
uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. The forward-looking statements included in this news
release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise unless required by applicable securities
legislation.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tetra-bio-pharma-signs-license-agreement-with-thorne-for-a-prebiotic-dietary-supplement-301486986.html
SOURCE Tetra Bio-Pharma Inc.